Imaging company Exact Imaging revealed on Wednesday the receipt of Health Canada's approval for its FusionVu application for micro-ultrasound/MRI fusion using the ExactVu high resolution micro-ultrasound system for the highest real-time resolution for targeted prostate imaging and biopsy.
This approval allows the company's Canadian customers to use the FusionVu application.
In addition, the company's ExactVu micro-ultrasound system and FusionVu have received regulatory approval in the EU (CE Mark), the US(FDA 510(k)) and Canada (Health Canada medical device license).
The company said the ExactVu micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and is an extension of the current urological workflow. The urologists are able to visualise areas of interest in the prostate and specifically target biopsies at those areas using the Exact Imaging platform.
Laronix and Greater Baltimore Medical Center launch Laronix MIRA Voice investigational study
BD receives CE Mark for Revello vascular covered stent
GAIA and Daiichi Sankyo Europe partner on digital therapeutic for cardiovascular care
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
BD receives FDA clearance for Surgiphor 1000mL irrigation system
Galderma secures EU, US and Canada approval for new Restylane syringe
Organon licenses MIUDELLA IUD from Sebela Pharmaceuticals
Advita Ortho updates Chime clinical exchange application
Philips launches InkSpace Imaging Snuggle coil for 3.0T MRI systems
Realheart secures European patent for artificial heart technology
Median Technologies secures FDA clearance for AI lung cancer screening software
Eli Lilly to invest over USD3.5bn in new Pennsylvania plant
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
Zylox-Tonbridge agrees staged acquisition of Germany's Optimed